Can Upadacitinib Be Used for Acute Flares of Ulcerative Colitis?
Yes, upadacitinib can be used for acute severe ulcerative colitis (ASUC) flares and demonstrates rapid efficacy with acceptable safety, though this represents off-label use as it is not FDA-approved specifically for acute flares. The evidence shows it works both as rescue therapy after steroid failure and as sequential salvage after infliximab failure.
Clinical Context and Evidence Base
The 2025 British Society of Gastroenterology guidelines 1 and 2024 AGA guidelines 2 establish upadacitinib as a high-efficacy medication for moderate-to-severe ulcerative colitis, with high certainty evidence showing large benefits for both induction and maintenance of remission. The induction dose is 45 mg once daily 1, which achieves clinical remission in approximately 29% of patients by week 10 compared to 3.7% with placebo 2.
Use in Acute Severe UC: Real-World Evidence
Multiple recent studies demonstrate upadacitinib's effectiveness specifically in ASUC:
- Rapid onset of action: Symptoms and C-reactive protein improve by week 1 and are sustained through week 48 3
- Colectomy rates: Range from 16-33% at 90 days to 1 year across studies 3, 4, 5, 6
- Clinical remission: 60% at week 1,51-83% in steroid-free remission among those avoiding colectomy 3, 5
Rescue vs Sequential Salvage Therapy
Upadacitinib can be used in two scenarios for acute flares:
- Rescue therapy (after IV corticosteroid failure): Used in 69% of patients in one large cohort 4
- Sequential salvage (after both IV steroids AND infliximab failure): Used in 31% of patients, with 86% having prior IFX exposure in another cohort 3
Sequential salvage therapy resulted in numerically higher colectomy rates (38% vs 30%) but did not reach statistical significance 4, suggesting both approaches are viable.
Comparative Effectiveness
When compared to tofacitinib for ASUC:
- Upadacitinib shows superior long-term outcomes: Significantly lower colectomy rate at week 52 (23.4% vs 42.5%, p=0.022) 4
- Faster initial response: 84% vs 54% response rate between days 3-7 (p=0.02) 7
- Similar effectiveness at intermediate timepoints: Response/remission comparable at days 98 and 182 7
Safety Profile in Acute Flares
Adverse events occurred in 24% of patients, with most being non-severe 3. Specific concerns include:
- Venous thromboembolism: 2-4% incidence reported 5, 6
- Infections: Generally low rates in acute setting
- Overall discontinuation: 48% by week 48, primarily due to primary non-response (42%) or secondary loss of response (46%) 3
Important Caveats and Risk Mitigation
The BSG guidelines 1 emphasize JAK inhibitors should be used with caution in patients with:
- Risk factors for venous thromboembolism
- Cardiovascular risk factors (age >65, smoking history)
- Increased cancer risk
- Active or chronic infections
Higher baseline CRP predicted colectomy in one study 3, suggesting patients with extremely elevated inflammatory markers may have higher failure rates.
Practical Algorithm for Use
For ASUC patients failing IV corticosteroids:
- First-line rescue: Consider upadacitinib 45 mg daily OR infliximab
- After infliximab failure: Upadacitinib as sequential salvage is effective (52% continuation at 48 weeks) 3
- Monitor closely: Assess response by day 3-7; if no improvement, consider colectomy
- Screen for VTE risk: Implement prophylaxis if indicated given hospitalized status
Upadacitinib may provide sufficient disease control to prevent or delay colectomy, or serve as a bridge to alternative therapies 3, making it a valuable option in the acute setting despite being off-label for this specific indication.